Loading...

Forthal, Donald N

Title(s)Professor, Medicine
Phone(949) 824-3366
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection
    NIH/NIAID R01AI118581Jun 15, 2015 - May 31, 2020
    Role: Principal Investigator
    The impact of antibody and pH on female-to-male SIV infection
    NIH/NIAID R01AI102715Jul 6, 2012 - Jun 30, 2016
    Role: Principal Investigator
    Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
    NIH/NIAID R01AI090656Jun 14, 2010 - May 31, 2014
    Role: Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH/NIAID R33AI079775May 1, 2009 - Jul 31, 2014
    Role: Co-Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH/NIAID R21AI079775May 1, 2009 - Aug 15, 2011
    Role: Principal Investigator
    Protective immunity against HIV: the role of IgG subclass and glycosylation
    NIH/NIAID R21AI078477Mar 1, 2008 - Feb 28, 2011
    Role: Principal Investigator
    Fcy Receptor Polymorphisms and Risk of HIV Infection
    NIH/NIAID R21AI073147Jul 15, 2007 - Jun 30, 2009
    Role: Principal Investigator
    Novel Biological Activities of Anti-Viral Antibody
    NIH/NIAID R01AI052039Jun 1, 2002 - May 31, 2007
    Role: Principal Investigator
    IMMUNOPROPHYLAXIS--DEFINING PROTECTIVE ANTIBODY FUNCTION
    NIH/NIAID R03AI044610Jun 1, 1999 - May 31, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gach JS, Mara KJV, LaBranche CC, van Gils MJ, McCoy LE, Klasse PJ, Montefiori DC, Sanders RW, Moore JP, Forthal DN. Antibody responses elicited by immunization with BG505 trimer-immune complexes. J Virol. 2019 Aug 02. PMID: 31375582.
      View in: PubMed
    2. Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. J Virol. 2019 Feb 01; 93(3). PMID: 30429343.
      View in: PubMed
    3. Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. J Virol. 2019 Feb 01; 93(3). PMID: 30429340.
      View in: PubMed
    4. Forthal D, Finzi A. Blocking HIV-1 replication: are Fc-Fc? receptor interactions required? J Clin Invest. 2019 Jan 02; 129(1):53-54. PMID: 30475231.
      View in: PubMed
    5. Forthal DN, Finzi A. Antibody-dependent cellular cytotoxicity in HIV infection. AIDS. 2018 Nov 13; 32(17):2439-2451. PMID: 30234611.
      View in: PubMed
    6. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med. 2018 Jun; 24(6):847-856. PMID: 29785023.
      View in: PubMed
    7. Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. J Virol. 2018 01 15; 92(2). PMID: 29093095.
      View in: PubMed
    8. Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu KT, Sharma B, Gratton E, Forthal DN. Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathog. 2017 12; 13(12):e1006793. PMID: 29281723.
      View in: PubMed
    9. Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME. Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol. 2016 12 15; 197(12):4603-4612. PMID: 27913647.
      View in: PubMed
    10. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G. Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 10 06; 22(10):1192. PMID: 27711066.
      View in: PubMed
    11. Gach JS, Venzon D, Vaccari M, Keele BF, Franchini G, Forthal DN. Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. J Virol. 2016 10 01; 90(19):8487-95. PMID: 27440881.
      View in: PubMed
    12. Gordon SN, Liyanage NP, Doster MN, Vaccari M, Vargas-Inchaustegui DA, Pegu P, Schifanella L, Shen X, Tomaras GD, Rao M, Billings EA, Schwartz J, Prado I, Bobb K, Zhang W, Montefiori DC, Foulds KE, Ferrari G, Robert-Guroff M, Roederer M, Phan TB, Forthal DN, Stablein DM, Phogat S, Venzon DJ, Fouts T, Franchini G. Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. J Immunol. 2016 10 01; 197(7):2726-37. PMID: 27591322.
      View in: PubMed
    13. Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One. 2016; 11(8):e0160341. PMID: 27500639; PMCID: PMC4976892.
    14. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 07; 22(7):762-70. PMID: 27239761.
      View in: PubMed
    15. Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Apr; 90(8):4133-4149. PMID: 26865719.
      View in: PubMed
    16. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol Immunol. 2016 Feb; 70:94-103. PMID: 26748387.
      View in: PubMed
    17. Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. EBioMedicine. 2015 Oct; 2(10):1464-77. PMID: 26629541.
      View in: PubMed
    18. Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal DN, Altmann F, Steinkellner H, Mach L. Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc Natl Acad Sci U S A. 2015 Oct 13; 112(41):12675-80. PMID: 26417081.
      View in: PubMed
    19. Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015 Aug; 11(8):e1005042. PMID: 26237403.
      View in: PubMed
    20. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. PLoS One. 2015; 10(7):e0133509. PMID: 26226263.
      View in: PubMed
    21. Dotsey EY, Gorlani A, Ingale S, Achenbach CJ, Forthal DN, Felgner PL, Gach JS. A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One. 2015; 10(5):e0125581. PMID: 25938510.
      View in: PubMed
    22. Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine. 2015 Apr 21; 33(17):2086-95. PMID: 25769884.
      View in: PubMed
    23. Chromikova V, Mader A, Hofbauer S, Göbl C, Madl T, Gach JS, Bauernfried S, Furtmüller PG, Forthal DN, Mach L, Obinger C, Kunert R. Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta. 2015 Oct; 1854(10 Pt A):1536-44. PMID: 25748881.
      View in: PubMed
    24. Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine. 2014 Nov 12; 32(48):6527-36. PMID: 25245933.
      View in: PubMed
    25. Forthal DN. Functions of Antibodies. Microbiol Spectr. 2014 Aug 15; 2(4):1-17. PMID: 25215264.
      View in: PubMed
    26. Forthal DN. Functions of Antibodies. Microbiol Spectr. 2014 Aug; 2(4):AID-0019-2014. PMID: 26104200.
      View in: PubMed
    27. Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits. Clin Vaccine Immunol. 2014 Aug; 21(8):1086-93. PMID: 24872518.
      View in: PubMed
    28. Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal DN. Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge. J Infect Dis. 2015 Jan 01; 211(1):45-52. PMID: 24850790.
      View in: PubMed
    29. Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology. 2014 Jan 20; 11:8. PMID: 24444350.
      View in: PubMed
    30. Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One. 2014; 9(1):e85371. PMID: 24454852.
      View in: PubMed
    31. Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog. 2013; 9(11):e1003776. PMID: 24278022.
      View in: PubMed
    32. Forthal D, Hope TJ, Alter G. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS. 2013 Sep; 8(5):393-401. PMID: 23924999.
      View in: PubMed
    33. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One. 2013; 8(8):e72054. PMID: 23991039.
      View in: PubMed
    34. Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal DN, Hessell AJ, Haigwood NL. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol. 2013 Oct; 87(19):10447-59. PMID: 23885083.
      View in: PubMed
    35. Gorlani A, Forthal DN. Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res. 2013 Jul; 11(5):421-6. PMID: 24191936.
      View in: PubMed
    36. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013 Jun 01; 27(9):F13-20. PMID: 23775002.
      View in: PubMed
    37. Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J. Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):31-3. PMID: 23344546.
      View in: PubMed
    38. Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S, Urban L, Landucci G, Fischer R, Jiang X. Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One. 2013; 8(3):e58724. PMID: 23533588.
      View in: PubMed
    39. Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol. 2013 Mar; 87(6):3538-48. PMID: 23325681.
      View in: PubMed
    40. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fc? receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012 Oct 04; 120(14):2836-42. PMID: 22915639.
      View in: PubMed
    41. Forthal DN, Phan TB, Slepenkin AV, Landucci G, Chu H, Elofsson M, Peterson E. In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Agents. 2012 Oct; 40(4):354-60. PMID: 22819150.
      View in: PubMed
    42. Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology. 2012 Jul 17; 9:57. PMID: 22805180.
      View in: PubMed
    43. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc?RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012 Jun; 86(11):6189-96. PMID: 22457527.
      View in: PubMed
    44. McBurney SP, Landucci G, Forthal DN, Ross TM. Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses. 2012 Sep; 28(9):1063-72. PMID: 22214267.
      View in: PubMed
    45. Rasmussen RA, Siddappa NB, Lakhashe SK, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-Guroff M, Montefiori DC, Forthal DN, O'Connor D, Ruprecht RM. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS. 2012 Jan 14; 26(2):149-55. PMID: 21941166.
      View in: PubMed
    46. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Jan 04; 482(7383):89-93. PMID: 22217938.
      View in: PubMed
    47. Forthal DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, Phan T. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS. 2011 Nov 13; 25(17):2099-104. PMID: 21832933.
      View in: PubMed
    48. Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine. 2011 Dec 09; 30(1):78-94. PMID: 22037204.
      View in: PubMed
    49. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. Fc-glycosylation influences Fc? receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol. 2010 Dec 01; 185(11):6876-82. PMID: 21041724.
      View in: PubMed
    50. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010 Oct; 16(10):1117-9. PMID: 20890292.
      View in: PubMed
    51. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med. 2010 Apr 12; 207(4):763-76. PMID: 20368576; PMCID: PMC2856026.
    52. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010 Feb; 84(3):1302-13. PMID: 19906907.
      View in: PubMed
    53. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 2009 Sep; 4(5):388-93. PMID: 20048702.
      View in: PubMed
    54. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal DN, Self SG, Carville A, Mansfield K, Goudsmit J. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2009 Sep; 83(18):9584-90. PMID: 19553307.
      View in: PubMed
    55. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 May; 5(5):e1000433. PMID: 19436712.
      View in: PubMed
    56. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009 Jan 01; 457(7225):87-91. PMID: 18997770.
      View in: PubMed
    57. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63. PMID: 18842730.
      View in: PubMed
    58. Eastman D, Piantadosi A, Wu X, Forthal DN, Landucci G, Kimata JT, Overbaugh J. Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses. Virol J. 2008 Aug 04; 5:90. PMID: 18680596.
      View in: PubMed
    59. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol. 2007 Dec 01; 179(11):7916-23. PMID: 18025239.
      View in: PubMed
    60. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007 Sep 06; 449(7158):101-4. PMID: 17805298.
      View in: PubMed
    61. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007 May 15; 178(10):6596-603. PMID: 17475891.
      View in: PubMed
    62. Miller CJ, Genescà M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol. 2007 May; 81(10):5024-35. PMID: 17329327.
      View in: PubMed
    63. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006 Sep 15; 177(6):4028-36. PMID: 16951366.
      View in: PubMed
    64. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006 Sep; 80(18):9217-25. PMID: 16940533.
      View in: PubMed
    65. Van Rompay KK, Blackwood EJ, Landucci G, Forthal D, Marthas ML. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol J. 2006 Apr 03; 3:22. PMID: 16584561.
      View in: PubMed
    66. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005 Feb 18; 19(3):295-302. PMID: 15718840.
      View in: PubMed
    67. Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol. 2005 Feb; 79(4):2042-9. PMID: 15681406; PMCID: PMC546539.
    68. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005 Mar 01; 191(5):654-65. PMID: 15688278.
      View in: PubMed
    69. Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli EV, McCutchan JA, Haubrich RH. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther. 2004 Oct; 9(5):753-61. PMID: 15535413.
      View in: PubMed
    70. Becerra JC, Arthur JF, Landucci GR, Forthal DN, Theuer CP. CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery. 2003 Apr; 133(4):404-10. PMID: 12717358.
      View in: PubMed
    71. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002 Oct 18; 16(15):F33-40. PMID: 12370520.
      View in: PubMed
    72. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP, Hwang J, Leedom JM, Tilles J, McCutchan JA. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis. 2001 Oct 01; 33(7):1060-8. PMID: 11528581.
      View in: PubMed
    73. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001 Aug; 75(15):6953-61. PMID: 11435575; PMCID: PMC114423.
    74. Reddy SV, Kurihara N, Menaa C, Landucci G, Forthal D, Koop BA, Windle JJ, Roodman GD. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology. 2001 Jul; 142(7):2898-905. PMID: 11416009.
      View in: PubMed
    75. Forthal DN, Landucci G, Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):553-61. PMID: 11350669.
      View in: PubMed
    76. Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001 Mar 30; 15(5):609-15. PMID: 11316998.
      View in: PubMed
    77. Forthal DN, Phan T, Landucci G. Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells. Transpl Infect Dis. 2001; 3 Suppl 2:31-4. PMID: 11926747.
      View in: PubMed
    78. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Muñoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB. Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol. 2000 May; 74(9):3967-74. PMID: 10756008.
      View in: PubMed
    79. Atabani S, Landucci G, Steward MW, Whittle H, Tilles JG, Forthal DN. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines. Clin Diagn Lab Immunol. 2000 Jan; 7(1):111-3. PMID: 10618288.
      View in: PubMed
    80. Forthal DN. Cytotoxic T lymphocyte precursors in persons with repeated exposure to human immunodeficiency virus. J Infect Dis. 1999 Oct; 180(4):1406-7. PMID: 10479184.
      View in: PubMed
    81. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999 Oct; 180(4):1338-41. PMID: 10479168.
      View in: PubMed
    82. Dunne MW, Bozzette S, McCutchan JA, Dubé MP, Sattler FR, Forthal D, Kemper CA, Havlir D. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet. 1999 Sep 11; 354(9182):891-5. PMID: 10489947.
      View in: PubMed
    83. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dubé MP, Hwang JY, McCutchan JA. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999 Jun 18; 13(9):1099-107. PMID: 10397541.
      View in: PubMed
    84. Havlir DV, Dubé MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998 Dec; 27(6):1369-75. PMID: 9868644.
      View in: PubMed
    85. Forthal DN, Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods. 1998 Nov 01; 220(1-2):129-38. PMID: 9839934.
      View in: PubMed
    86. Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. J Infect Dis. 1998 Mar; 177(3):595-9. PMID: 9498437.
      View in: PubMed
    87. Forthal DN, Landucci G, Robinson WE. Lymphokine-activated cytotoxicity in peripheral blood mononuclear cells of severely immunocompromised HIV-infected patients. Scand J Immunol. 1997 Jan; 45(1):91-5. PMID: 9010505.
      View in: PubMed
    88. McDougall B, Nymark MH, Landucci G, Forthal D, Robinson WE. Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3. Scand J Immunol. 1997 Jan; 45(1):103-11. PMID: 9010507.
      View in: PubMed
    89. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, Bozzette SA, McCutchan JA. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996 Aug 08; 335(6):392-8. PMID: 8676932.
      View in: PubMed
    90. Forthal DN, Landucci G, Habis A, Laxer M, Javato-Laxer M, Tilles JG, Janoff EN. Age, sex, and household exposure are associated with the acute measles-specific antibody-dependent cellular cytotoxicity antibody response. J Infect Dis. 1995 Dec; 172(6):1587-91. PMID: 7594722.
      View in: PubMed
    91. Forthal DN, Landucci G, Gorny MK, Zolla-Pazner S, Robinson WE. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res Hum Retroviruses. 1995 Sep; 11(9):1095-9. PMID: 8554906.
      View in: PubMed
    92. Bozzette SA, Forthal D, Sattler FR, Kemper C, Richman DD, Tilles JG, Leedom J, McCutchan JA. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Am J Med. 1995 Feb; 98(2):177-82. PMID: 7847434.
      View in: PubMed
    93. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct; 19(4):741-5. PMID: 7803641.
      View in: PubMed
    94. Aarnaes SL, Blanding J, Speier S, Forthal D, de la Maza LM, Peterson EM. Comparison of the ProSpecT and Color Vue enzyme-linked immunoassays for the detection of Cryptosporidium in stool specimens. Diagn Microbiol Infect Dis. 1994 Aug; 19(4):221-5. PMID: 7851085.
      View in: PubMed
    95. Forthal DN, Landucci G, Habis A, Zartarian M, Katz J, Tilles JG. Measles virus-specific functional antibody responses and viremia during acute measles. J Infect Dis. 1994 Jun; 169(6):1377-80. PMID: 8195621.
      View in: PubMed
    96. Forthal DN, Landucci G, Katz J, Tilles JG. Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J Infect Dis. 1993 Oct; 168(4):1020-3. PMID: 8376813.
      View in: PubMed
    97. Forthal DN, Blanding J, Aarnaes S, Peterson EM, de la Maza LM, Tilles JG. Comparison of different methods and cell lines for isolating measles virus. J Clin Microbiol. 1993 Mar; 31(3):695-7. PMID: 8458965.
      View in: PubMed
    98. Forthal DN, Aarnaes S, Blanding J, de la Maza L, Tilles JG. Degree and length of viremia in adults with measles. J Infect Dis. 1992 Aug; 166(2):421-4. PMID: 1634814.
      View in: PubMed
    99. Nzilambi N, De Cock KM, Forthal DN, Francis H, Ryder RW, Malebe I, Getchell J, Laga M, Piot P, McCormick JB. The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire. N Engl J Med. 1988 Feb 04; 318(5):276-9. PMID: 3336420.
      View in: PubMed
    100. Getchell JP, Hicks DR, Svinivasan A, Heath JL, York DA, Malonga M, Forthal DN, Mann JM, McCormick JB. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis. 1987 Nov; 156(5):833-7. PMID: 3309075.
      View in: PubMed